Novel agents and evolving strategies in myelofibrotive neoplasm: an update from 2022 ASH annual conference
Abstract Myelofibrosis (MF) is a disorder characterized by the proliferation of myeloid precursors, commonly due to overactive JAK signaling. The discovery of the JAK2V617F mutation and subsequent development of JAK inhibitors (JAKi) results in reduced spleen size, improved symptom, and enhanced sur...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-05-01
|
| Series: | Journal of Hematology & Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13045-023-01446-0 |
| _version_ | 1797827372133646336 |
|---|---|
| author | Andrew Wang James Liu Jeffrey J. Pu |
| author_facet | Andrew Wang James Liu Jeffrey J. Pu |
| author_sort | Andrew Wang |
| collection | DOAJ |
| description | Abstract Myelofibrosis (MF) is a disorder characterized by the proliferation of myeloid precursors, commonly due to overactive JAK signaling. The discovery of the JAK2V617F mutation and subsequent development of JAK inhibitors (JAKi) results in reduced spleen size, improved symptom, and enhanced survival in MF patients. However, there are unmet needs of additional novel targeted therapies for this incurable disease due to the limited utility of first-generation JAKis, which are associated with dose-limiting cytopenia and disease recurrence. New targeted treatment strategies for MF are on the horizon. We are here to discuss the latest clinical research findings presented in the 2022 ASH Annual Meeting. |
| first_indexed | 2024-04-09T12:47:13Z |
| format | Article |
| id | doaj.art-553ada29c46b4d01941f42ab8c4d40f5 |
| institution | Directory Open Access Journal |
| issn | 1756-8722 |
| language | English |
| last_indexed | 2024-04-09T12:47:13Z |
| publishDate | 2023-05-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Hematology & Oncology |
| spelling | doaj.art-553ada29c46b4d01941f42ab8c4d40f52023-05-14T11:25:04ZengBMCJournal of Hematology & Oncology1756-87222023-05-011611510.1186/s13045-023-01446-0Novel agents and evolving strategies in myelofibrotive neoplasm: an update from 2022 ASH annual conferenceAndrew Wang0James Liu1Jeffrey J. Pu2Pennsylvania State UniversityHopkins SchoolBoston VA Medical Center/Brigham and Woman Hospital, Harvard Medical SchoolAbstract Myelofibrosis (MF) is a disorder characterized by the proliferation of myeloid precursors, commonly due to overactive JAK signaling. The discovery of the JAK2V617F mutation and subsequent development of JAK inhibitors (JAKi) results in reduced spleen size, improved symptom, and enhanced survival in MF patients. However, there are unmet needs of additional novel targeted therapies for this incurable disease due to the limited utility of first-generation JAKis, which are associated with dose-limiting cytopenia and disease recurrence. New targeted treatment strategies for MF are on the horizon. We are here to discuss the latest clinical research findings presented in the 2022 ASH Annual Meeting.https://doi.org/10.1186/s13045-023-01446-0Myelofibrotive neoplasmTargeted therapyClinical research |
| spellingShingle | Andrew Wang James Liu Jeffrey J. Pu Novel agents and evolving strategies in myelofibrotive neoplasm: an update from 2022 ASH annual conference Journal of Hematology & Oncology Myelofibrotive neoplasm Targeted therapy Clinical research |
| title | Novel agents and evolving strategies in myelofibrotive neoplasm: an update from 2022 ASH annual conference |
| title_full | Novel agents and evolving strategies in myelofibrotive neoplasm: an update from 2022 ASH annual conference |
| title_fullStr | Novel agents and evolving strategies in myelofibrotive neoplasm: an update from 2022 ASH annual conference |
| title_full_unstemmed | Novel agents and evolving strategies in myelofibrotive neoplasm: an update from 2022 ASH annual conference |
| title_short | Novel agents and evolving strategies in myelofibrotive neoplasm: an update from 2022 ASH annual conference |
| title_sort | novel agents and evolving strategies in myelofibrotive neoplasm an update from 2022 ash annual conference |
| topic | Myelofibrotive neoplasm Targeted therapy Clinical research |
| url | https://doi.org/10.1186/s13045-023-01446-0 |
| work_keys_str_mv | AT andrewwang novelagentsandevolvingstrategiesinmyelofibrotiveneoplasmanupdatefrom2022ashannualconference AT jamesliu novelagentsandevolvingstrategiesinmyelofibrotiveneoplasmanupdatefrom2022ashannualconference AT jeffreyjpu novelagentsandevolvingstrategiesinmyelofibrotiveneoplasmanupdatefrom2022ashannualconference |